Lingzhi Hong, MD, PhD

Peer-Reviewed Articles

1. Muneer A, Showkatian E, Saad MB, Hong L, Li S, Salehjahromi M, Aminu M, Sujit SJ, Xu H, Waqas M, Zafar A, Shroff G, Wu CC, Carter BW, Chang JY, Liao Z, Altan M, Vokes NI, Cascone T, Le X, Haymaker CL, Wistuba II, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee J, Lou Y, Heymach JV, Zhang J, Wu J. Deep learning of CT imaging predicts PD-L1 expression and immunotherapy response in metastatic NSCLC: A multi-center study. Cancer Lett, 2026. e-Pub 2026. PMID: 42314966.
2. Gariazzo E, Elkrief A, Concannon K, Ognissanti D, Dodi A, Favorito V, Federico AD, Giglio AD, Brunetti L, Santo V, Pecci F, Aldea M, Garbo E, Alessi JV, LoPiccolo J, Paoloni F, Nishino M, Sholl LM, Florez N, Rotow J, Frumm SM, Hong L, Zhang J, Gibbons D, Wang X, Landi L, Cipriani L, Rakaee M, Cortellini A, Tiseo M, Cappuzzo F, Ardizzoni A, Awad MM, Heymach JV, Scalera S, Maugeri-Saccà M, Metro G, Vokes N, Schoenfeld A, Ricciuti B. Clinical outcomes and predictors of response to PD-(L) 1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco. Clin Cancer Res, 2026. e-Pub 2026. PMID: 42149140.
3. Lei G, Lu Z, Xu Z, Braun C, Huo D, Gao J, Tan L, Hong T, Wu S, Sun M, Zhao X, Li Q, Chen X, Yan Y, Lee H, Mao C, Zhuang L, Ku L, Puebla N, Barsoumian H, Yao J, Hong L, Zhang J, Tran H, Lee JJ, Gibbons D, Vaporciyan A, Heymach J, Lin C, Gottlieb E, You MJ, Welsh JW, Lin SH, Zang X, Li Z, Gan B. Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell, 2026. e-Pub 2026. PMID: 42330950.
4. Liu X, Stamboulian M, Borgeaud M, Zhu E, Weipert C, Zhang N, Nilsson MB, Wang K, Hong L, Wang J, Morris BB, Heeke S, Robichaux JP, Lewis C, Drusbosky L, Chen H, Yang Y, He J, Cai L, Wu J, Zhang J, Alfredo A, Heymach JV, Le X. Compound EGFR Mutations Are Predominantly P-Loop and Alpha-C Helix Compressing Mutations With Increased Responsiveness to Second- Versus Third-Generation Tyrosine Kinase Inhibitors. J Thorac Oncol, 2026. e-Pub 2026. PMID: 42191070.
5. Parma M, Wang K, Taslicay CA, Shah K, Singhi EK, Rivera M, Soto LS, Wang W, Hong L, Li Z, Altan M, Vega MF, Groot PD, Halliday A, Jacome J, Zhang J, Le X, Pozadzides J, Tu J, Hume CB, Blumenschein G, Skoulidis F, Cascone T, Fossella F, Negrao MV, Vokes N, Gibbons D, Araujo H, Tsao A, Heymach JV, Byers LA, Gay CM, Zhang B. Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity. JCO Precis Oncol, 2026. e-Pub 2026. PMID: 42024839.
6. Federico AD, Hong L, Elkrief A, Thummalapalli R, Cooper AJ, Ricciuti B, Digumarthy S, Alessi JV, Gogia P, Hambelton GM, Pecci F, Makarem M, Gandhi MM, Garbo E, Giglio AD, Gagliano A, Sperandi F, Gelsomino F, Scalera S, Cipriani L, Marinelli D, Lamberti G, Shaverdian N, Haradon J, Nguyen T, Voligny E, Ladanyi M, Zhang J, Gibbons DL, Heymach JV, Nishino M, Rodig SJ, Pfaff K, Wang X, Rekhtman N, Sholl LM, Luo J, Johnson BE, Janne PA, Arvind R, Gainor JF, Maugeri-Saccà M, Ardizzoni A, Heist RS, Arbour KC, Schoenfeld AJ, Vokes NI, Awad MM. TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors. J Thorac Oncol, 2026. e-Pub 2026. PMID: 41690364.
7. Nilsson MB, Le X, Poteete A, Yu X, He J, Huang Q, Shibata Y, Liu X, Moran C, Alizadeh AA, Diehn M, Wakelee H, Almanza D, Soltys S, Sugio T, Mutter J, Kang X, Wang R, Jun S, Esfahani MS, Tran H, Xi Y, Hong L, Huo X, Kumar A, Ren X, Oguchi K, Minamiguchi K, Weipert CM, Wang J, Kittler R, Heymach JV. Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs. J Thorac Oncol, 2026. e-Pub 2026. PMID: 41548807.
8. Han X, Li W, Lin J, Li S, Saad MB, Kitsel Y, Heeke S, Hong L, Mohamed MQ, Le X, Vokes N, Godoy MC, Carter BW, Shroff GS, Eapen G, Byers LA, Vaporciyan AA, Gibbons DL, Heymach J, Wu CC, Zhang J, Wu J. Development of PET/CT-clinical nomograms for predicting lymph node metastasis in primary lung cancer. Eur Radiol, 2025. e-Pub 2025. PMID: 41405691.
9. Li, H, Hong, L, Rocha, P, Bach, R, Solis Soto, LM, Rinsurongkawong, W, Zhang, B, Araujo, HA, Elamin, YY, Altan, M, Arrechedera, C, Zhou, J, Khan, KB, Lu, W, Young, E, Gay, CM, Cascone, T, Byers, LA, Skoulidis, F, Blumenschein, GR, Fossella, FV, Tsao, A, Vailati Negrao, M, Vokes, N, Wu, J, Tran, HT, Wistuba, II, Lee, JJ, Gibbons, DL, Vaporciyan, AA, Heymach, JV, Le, X, Zhang, J. MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer. Cancers 17(23), 2025. e-Pub 2025. PMID: 41375002.
10. Salehjahromi, M, Li, H, Showkatian, E, Saad, M, Qayati, M, Ismail, SM, Sujit, S, Muneer, A, Aminu, M, Hong, L, Han, X, Heeke, S, Cascone, T, Le, X, Vokes, N, Gibbons, DL, Toumazis, I, Ostrin, EJ, Antonoff, MB, Vaporciyan, AA, Jaffray, D, Kay, FU, Carter, B, Wu, CC, Godoy, M, Lee, JJ, Gerber, DE, Heymach, JV, Zhang, J, Wu, J. Radiomics for Dynamic Lung Cancer Risk Prediction in USPSTF-Ineligible Patients. Cancers 17(21), 2025. e-Pub 2025. PMID: 41228201.
11. Aminu M, Zhu B, Vokes N, Chen H, Hong L, Li J, Fujimoto J, Chaib M, Yang Y, Wang B, Poteete A, Nilsson M, Le X, Cascone T, Jaffray D, Navin N, Wang T, Byers LA, Gibbons DL, Heymach J, Chen K, Cheng C, Zhang J, Wu J. CoCo-ST detects global and local biological structures in spatial transcriptomics datasets. Nature Cell Biology, 2025. e-Pub 2025. PMID: 41083603.
12. Le X, Robichaux JP, Nilsson M, Vijayan RSK, Ravichandran A, Wu J, Elamin YY, Hong L, Pei J, He J, Patel S, Udagawa H, Mani S, Jang CW, Clarke JM, Tchekmedyian N, Goldman JW, Socinski M, Bhat G, Leu S, Bunn V, Su Z, Vincent S, Lawson JW, Cross JB, Heymach JV. Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity. Nat Commun 16(1):8358, 2025. e-Pub 2025. PMID: 40993146.
13. Pecci F, Li H, Federico AD, Wu J, Chen H, Gariazzo E, Mantuano F, Garbo E, Aldea M, Santo V, Gibbons D, Tran H, Paoloni F, de Almeida GR, Metro G, Giglio AD, Gelsomino F, Wang X, Tiseo M, Rotow J, Ardizzoni A, Lee J, Awad MM, Addeo A, Hong L, Negrao MV, Janne PA, Heymach JV, Zhang J, Ricciuti B, Le X. First-line MET tyrosine kinase inhibitors versus immunotherapy±chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC. Clinical Cancer Research, 2025. e-Pub 2025. PMID: 40864503.
14. Hong L, Di Federico A, Liu B, Cooper AJ, Alessi JV, Clark P, Rinsurongkawong W, Young C, Li H, Qin K, Aminu M, Santo V, Elamin Y, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Lee JJ, Le X, Wu J, Roy-Chowdhuri S, Routbort MJ, Futreal PA, Heymach JV, Awad MM, Schoenfeld AJ, Zhang J, Ricciuti B, Deng L, Vokes NI. Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study. J Thorac Oncol, 2025. e-Pub 2025. PMID: 40716572.
15. Saad MB, Al-Tashi Q, Hong L, Verma V, Li W, Boiarsky D, Li S, Petranovic M, Wu CC, Carter BW, Shroff GS, Cascone T, Le X, Elamin YY, Altan M, Heeke S, Sheshadri A, Chang JY, Lee PP, Liao Z, Gibbons DL, Vaporciyan AA, Lee JJ, Wistuba II, Haymaker C, Mirjalili S, Jaffray D, Gainor JF, Lou Y, Di Federico A, Pecci F, Awad M, Ricciuti B, Heymach JV, Vokes NI, Zhang J, Wu J. Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC. Nat Commun 16(1):6828, 2025. e-Pub 2025. PMID: 40707438.
16. Zhu B, Chen P, Aminu M, Li JR, Fujimoto J, Tian Y, Hong L, Chen H, Hu X, Li C, Vokes N, Moreira AL, Gibbons DL, Solis Soto LM, Parra Cuentas ER, Shi O, Diao S, Ye J, Rojas FR, Vilar E, Maitra A, Chen K, Navin N, Nilsson M, Huang B, Heeke S, Zhang J, Haymaker CL, Velcheti V, Sterman DH, Kochat V, Padron WI, Alexandrov LB, Wei Z, Le X, Wang L, Fukuoka J, Lee JJ, Wistuba II, Pass HI, Davis M, Hanash S, Cheng C, Dubinett S, Spira A, Rai K, Lippman SM, Futreal PA, Heymach JV, Reuben A, Wu J, Zhang J. Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception. Cancer Cell 43(6):1125-1140.e10, 2025. e-Pub 2025. PMID: 40345189.
17. Li, H, Salehjahromi, M, Godoy, M, Qin, K, Plummer, CM, Zhang, Z, Hong, L, Heeke, S, Le, X, Vokes, N, Zhang, B, Araujo, HA, Altan, M, Wu, CC, Antonoff, MB, Ostrin, EJ, Gibbons, DL, Heymach, JV, Lee, JJ, Gerber, DE, Wu, J, Zhang, J. Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil Model. Cancers 17(9), 2025. e-Pub 2025. PMID: 40361426.
18. Federico A, Hong L, Elkrief A, Thummalapalli R, Cooper AJ, Ricciuti B, Digumarthy S, Alessi JV, Gogia P, Pecci F, Makarem M, Gandhi MM, Garbo E, Saini A, Giglio A, Favorito V, Scalera S, Cipriani L, Marinelli D, Haradon D, Nguyen T, Haradon J, Voligny E, Vaz V, Gelsomino F, Sperandi F, Melotti B, Ladanyi M, Zhang J, Gibbons DL, Heymach JV, Nishino M, Lindsay J, Rodig SJ, Pfaff K, Sholl LM, Wang X, Johnson BE, Jänne PA, Rekhtman N, Maugeri-Saccà M, Heist RS, Ardizzoni A, Awad MM, Arbour KC, Schoenfeld AJ, Vokes NI, Luo J. Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors. Ann Oncol 36(3):297-308, 2025. e-Pub 2025. PMID: 39637943.
19. Cooper, AJ, Arfe, A, Ricciuti, B, Gagné, A, Sholl, LM, Di Federico, A, Awad, MM, Aldea, M, Ghigna, MR, Grecea, M, Clark, P, Chaft, JE, Kris, MG, Riely, GJ, Rudin, CM, Dagogo-Jack, I, Mino-Kenudson, M, Hong, L, Kalhor, N, Vokes, N, Bowman, AS, Yang, SR, Rekhtman, N, Schoenfeld, AJ. Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors. JTO Clinical and Research Reports 6(1), 2025. e-Pub 2025. PMID: 39802817.
20. Hong L, Patel S, Drusbosky LM, Xiong Y, Chen R, Geng R, Heeke S, Nilsson M, Wu J, Heymach JV, Wang Y, Zhang J, Le X. Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 39354054.
21. Seth S, Chen R, Liu Y, Fujimoto J, Hong L, Reuben A, Varghese S, Behrens C, McDowell T, Soto LS, Haymaker C, Weisserdt A, Kalhor N, Wu J, Le X, Vokes N, Cheng C, Heymach JV, Gibbons DL, Futreal P, Wistuba II, Kadara H, Zhang J, Moran C, Zhang J. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes. Cancer Innovation, 2024. e-Pub 2024. PMID: 38947760.
22. Sujit SJ, Aminu M, Karpinets TV, Chen P, Saad MB, Salehjahromi M, Boom JD, Qayati M, George JM, Allen H, Antonoff MB, Hong L, Hu X, Heeke S, Tran HT, Le X, Elamin YY, Altan M, Vokes NI, Sheshadri A, Lin J, Zhang J, Lu Y, Behrens C, Godoy MCB, Wu CC, Chang JY, Chung C, Jaffray DA, Wistuba II, Lee JJ, Vaporciyan AA, Gibbons DL, Heymach J, Zhang J, Cascone T, Wu J. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat Commun 15(1):3152, 2024. e-Pub 2024. PMID: 38605064.
23. Salehjahromi, M, Karpinets, T, Sujit, S, Qayati, M, Chen, P, Aminu, M, Saad, MB, Bandyopadhyay, R, Hong, L, Sheshadri, A, Lin, J, Antonoff, MB, Sepesi, B, Ostrin, EJ, Toumazis, I, Huang, P, Cheng, C, Cascone, T, Vokes, N, Behrens, C, Siewerdsen, JH, Hazle, JD, Chang, JY, Zhang, J, Lu, Y, Godoy, M, Chung, C, Jaffray, D, Wistuba, II, Lee, JJ, Vaporciyan, AA, Gibbons, DL, Gladish, G, Heymach, JV, Wu, CC, Zhang, J, Wu, J. Synthetic PET from CT improves diagnosis and prognosis for lung cancer. Cell Reports Medicine 5(3), 2024. e-Pub 2024. PMID: 38471502.
24. Qin, K, Wang, K, Li, S, Hong, L, Padmakumar, P, Waree, R, Hubert, SM, Le, X, Vokes, N, Rai, K, Vaporciyan, AA, Gibbons, DL, Heymach, JV, Lee, JJ, Woodman, SE, Chung, C, Jaffray, D, Altan, M, Lou, Y, Zhang, J. Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy. Cancers 16(5), 2024. e-Pub 2024. PMID: 38473297.
25. Chen, P, Rojas Alvarez, F, Hu, X, Serrano, A, Zhu, B, Chen, H, Hong, L, Bandyoyadhyay, R, Aminu, M, Kalhor, N, Lee, JJ, El Hussein, S, Khoury, J, Pass, HI, Moreira, AL, Velcheti, V, Sterman, DH, Fukuoka, J, Tabata, K, Su, D, Ying, L, Gibbons, DL, Heymach, JV, Wistuba, II, Fujimoto, J, Solis Soto, LM, Zhang, J, Wu, J. Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma. Modern Pathology 36(12), 2023. e-Pub 2023. PMID: 37678674.
26. Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee J, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, Vaporciyan AA, Heymach JV, Zhang J, Le X. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol 19(3):500-506, 2023. e-Pub 2023. PMID: 38012986.
27. Thummalapalli, R, Ricciuti, B, Bandlamudi, C, Muldoon, D, Rizvi, H, Elkrief, A, Luo, J, Alessi, JV, Pecci, F, Lamberti, G, Di Federico, A, Hong, L, Zhang, J, Heymach, JV, Gibbons, DL, Plodkowski, AJ, Ravichandran, V, Donoghue, MT, Vanderbilt, C, Ladanyi, M, Rudin, CM, Kris, MG, Riely, GJ, Chaft, JE, Hellmann, MD, Vokes, N, Awad, MM, Schoenfeld, AJ. Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research 29(21):4408-4418, 2023. e-Pub 2023. PMID: 37432985.
28. Diao, S, Chen, P, Showkatian, E, Bandyopadhyay, R, Rojas Alvarez, F, Zhu, B, Hong, L, Aminu, M, Saad, MB, Salehjahromi, M, Muneer, A, Sujit, S, Behrens, MC, Gibbons, DL, Heymach, JV, Kalhor, N, Wistuba, II, Solis Soto, LM, Zhang, J, Qin, W, Wu, J. Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis. Cancers 15(19), 2023. e-Pub 2023. PMID: 37835518.
29. Wang, K, Du, R, Roy Chowdhuri, S, Li, ZT, Hong, L, Vokes, N, Elamin, YY, Bueno Hume, C, Skoulidis, F, Gay, CM, Blumenschein, GR, Fossella, FV, Tsao, A, Zhang, J, Karachaliou, N, O'Brate, A, Gann, CN, Lewis, J, Rinsurongkawong, W, Lee, JJ, Gibbons, DL, Vaporciyan, AA, Heymach, JV, Altan, M, Le, X. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clinical and Research Reports 4(8), 2023. e-Pub 2023. PMID: 37649681.
30. Saad, MB, Hong, L, Aminu, M, Vokes, N, Chen, P, Salehjahromi, M, Qin, K, Sujit, S, Lu, X, Young, E, Al-Tashi, Q, Qureshi, R, Wu, CC, Carter, B, Lin, SH, Lee, PP, Gandhi, S, Chang, JY, Li, R, Gensheimer, MF, Wakelee, HA, Neal, JW, Lee, HS, Cheng, C, Velcheti, V, Lou, Y, Petranovic, M, Rinsurongkawong, W, Le, X, Rinsurongkawong, V, Spelman, AR, Elamin, YY, Vailati Negrao, M, Skoulidis, F, Gay, CM, Cascone, T, Antonoff, MB, Sepesi, B, Lewis, J, Wistuba, II, Hazle, JD, Chung, C, Jaffray, D, Gibbons, DL, Vaporciyan, AA, Lee, JJ, Heymach, JV, Zhang, J, Wu, J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning. The Lancet Digital Health 5(7):e404-e420, 2023. e-Pub 2023. PMID: 37268451.
31. Hong, L, Aminu, M, Li, S, Lu, X, Petranovic, M, Saad, MB, Chen, P, Qin, K, Varghese, S, Rinsurongkawong, W, Rinsurongkawong, V, Spelman, AR, Elamin, YY, Vailati Negrao, M, Skoulidis, F, Gay, CM, Cascone, T, Gandhi, S, Lin, SH, Lee, PP, Carter, B, Wu, CC, Antonoff, MB, Sepesi, B, Lewis, J, Gibbons, DL, Vaporciyan, AA, Le, X, Lee, JJ, Roy Chowdhuri, S, Routbort, MJ, Gainor, J, Heymach, JV, Lou, Y, Wu, J, Zhang, J, Vokes, N. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nature communications 14(1), 2023. e-Pub 2023. PMID: 36755027.
32. Aminu, M, Yadav, D, Hong, L, Young, E, Edelkamp, P, Saad, MB, Salehjahromi, M, Chen, P, Sujit, S, Chen, MM, Sabloff, B, Gladish, G, de Groot, P, Godoy, M, Cascone, T, Vokes, N, Zhang, J, Brock, K, Daver, N, Woodman, SE, Tawbi, H, Sheshadri, A, Lee, JJ, Jaffray, D, Wu, CC, Chung, C, Wu, J. Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19. Cancers 15(1), 2023. e-Pub 2023. PMID: 36612278.
33. Vokes, N, Galan Cobo, A, Fernandez-Chas, M, Molkentine, D, Trevino, S, Druker, V, Qian, Y, Patel, S, Schmidt, S, Hong, L, Lewis, J, Rinsurongkawong, W, Rinsurongkawong, V, Lee, JJ, Vailati Negrao, M, Gibbons, DL, Vaporciyan, AA, Le, X, Wu, J, Zhang, J, Rigney, U, Iyer, S, Dean, E, Heymach, JV. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC. Clinical Cancer Research 29(23):4958-4972, 2023. e-Pub 2023. PMID: 37733794.
34. Coleman N, Marcelo KL, Hopkins JF, Khan NI, Du R, Hong L, Park E, Balsara B, Leoni M, Pickering C, Myers J, Heymach J, Albacker LA, Hong D, Gillison M, Le X. HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma. JCO Precis Oncol, 2023. e-Pub 2023. PMID: 36603172.
35. Chen, R, Li, J, Fujimoto, J, Hong, L, Hu, X, Quek, YK, Tang, M, Mitra, A, Behrens, MC, Chow, CW, Jiang, P, Little, L, Gumbs, C, Song, X, Zhang, J, Tan, D, Heymach, JV, Wistuba, II, Futreal, A, Gibbons, DL, Byers, LA, Zhang, J, Reuben, A. Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. Journal of Experimental and Clinical Cancer Research 41(1), 2022. e-Pub 2022. PMID: 35546239.
36. Hong, L, Lewis, WE, Nilsson, M, Patel, S, Varghese, S, Rivera, MJ, Du, R, Chen, P, Kemp, HN, Rinsurongkawong, W, Heeke, S, Spelman, AR, Elamin, YY, Vailati Negrao, M, Sepesi, B, Gibbons, DL, Lee, JJ, Wu, J, Vokes, N, Heymach, JV, Zhang, J, Le, X. Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers 14(14), 2022. e-Pub 2022. PMID: 35884533.
37. Ricciuti, B, Arbour, KC, Lin, JJ, Vajdi, A, Vokes, N, Hong, L, Zhang, J, Tolstorukov, MY, Li, YY, Spurr, LF, Cherniack, AD, Recondo, G, Lamberti, G, Wang, X, Venkatraman, D, Alessi, JV, Vaz, VR, Rizvi, H, Egger, J, Plodkowski, AJ, Khosrowjerdi, S, Digumarthy, S, Park, H, Vaz, N, Nishino, M, Sholl, LM, Barbie, DA, Altan, M, Heymach, JV, Skoulidis, F, Gainor, J, Hellmann, MD, Awad, MM. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. Journal of Thoracic Oncology 17(3):399-410, 2022. e-Pub 2022. PMID: 34740862.
38. Lewis, WE, Hong, L, Mott, FE, Simon, G, Wu, CC, Rinsurongkawong, W, Lee, JJ, Lam, VK, Heymach, JV, Zhang, J, Le, X. Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations. JTO Clinical and Research Reports 2(11), 2021. e-Pub 2021. PMID: 34820641.
39. Robichaux, JP, Le, X, Ramaswamy, SV, Hicks, JK, Heeke, S, Elamin, YY, Lin, Y, Udagawa, H, Skoulidis, F, Tran, HT, Varghese, S, He, J, Zhang, F, Nilsson, M, Hu, L, Poteete, A, Rinsurongkawong, W, Zhang, X, Ren, C, Liu, X, Hong, L, Zhang, J, Diao, L, Madison, RW, Schrock, AB, Saam, JR, Raymond, VM, Fang, B, Wang, J, Ha, MJ, Cross, JB, Gray, J, Heymach, JV. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 597(7878):732-737, 2021. e-Pub 2021. PMID: 34526717.
40. Vailati Negrao, M, Skoulidis, F, Montesion, M, Schulze, K, Bara, I, Shen, V, Xu, H, Hu, S, Sui, D, Elamin, YY, Le, X, Goldberg, ME, Murugesan, K, Wu, C, Zhang, J, Barreto, DS, Robichaux, JP, Reuben, A, Cascone, T, Gay, CM, Mitchell, KG, Hong, L, Rinsurongkawong, W, Roth, JA, Swisher, SG, Lee, JJ, Tsao, A, Papadimitrakopoulou, VA, Gibbons, DL, Glisson, BS, Singal, G, Miller, VA, Alexander, BM, Frampton, GM, Albacker, LA, Shames, DS, Zhang, J, Heymach, JV. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. Journal for immunotherapy of cancer 9(8), 2021. e-Pub 2021. PMID: 34376553.
41. Le, X, Hong, L, Hensel, CH, Chen, R, Kemp, HN, Coleman, N, Ciunci, CA, Liu, SV, Vailati Negrao, M, Yen, J, Xia, X, Scheuenpflug, J, Stroh, C, Juraeva, D, Tsao, A, Hong, DS, Raymond, VM, Paik, PK, Zhang, J, Heymach, JV. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precision Oncology 5:1802-1812, 2021. e-Pub 2021. PMID: 34957368.
42. Liu, X, Hong, L, Nilsson, M, Hubert, SM, Wu, S, Rinsurongkawong, W, Lewis, J, Spelman, AR, Roth, JA, Swisher, SG, He, Y, Lee, JJ, Fang, B, Heymach, JV, Zhang, J, Le, X. Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer 149:33-40, 2020. e-Pub 2020. PMID: 32956986.
43. Hong, L, Vailati Negrao, M, Dibaj, S, Chen, R, Reuben, A, Bohac, JM, Liu, X, Skoulidis, F, Gay, CM, Cascone, T, Mitchell, KG, Tran, HT, Le, X, Byers, LA, Sepesi, B, Altan, M, Elamin, YY, Fossella, FV, Kurie, JM, Lu, C, Mott, FE, Tsao, A, Rinsurongkawong, W, Lewis, J, Gibbons, DL, Glisson, BS, Blumenschein, GR, Roarty, EB, Futreal, A, Wistuba, II, Roth, JA, Swisher, SG, Papadimitrakopoulou, VA, Heymach, JV, Lee, JJ, Simon, G, Zhang, J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
44. Tang, Z, Chen, H, Hong, L, Tang, G, Toruner, GA, Wang, W, Roy Chowdhuri, S, Yin, W, Jung, HS, Gu, J, Routbort, MJ, Zhang, J, Khoury, J, Medeiros, LJ. Inconsistent intersample alk fish results in patients with lung cancer. Cancers 12(7):1-17, 2020. e-Pub 2020. PMID: 32674491.
45. Zhuo, M, Guan, YF, Yang, X, Hong, L, Wang, Y, Li, Z, Chen, R, Abbas, HA, Chang, L, Gong, Y, Wu, N, Zhong, J, Chen, W, Chen, H, Dong, Z, Zhu, X, Li, J, Wang, Y, An, T, Wu, M, Wang, Z, Wang, J, Roarty, EB, Rinsurongkawong, W, Lewis, J, Roth, JA, Swisher, SG, Lee, JJ, Heymach, JV, Wistuba, II, Kalhor, N, Yang, L, Yi, X, Futreal, A, Glisson, BS, Xia, X, Zhang, J, Zhao, J. The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma. Clinical Cancer Research 26(4):892-901, 2020. e-Pub 2020. PMID: 31694833.
46. Wei, X, Zhou, J, Hong, L, Xu, Z, Zhao, H, Wu, X, Chen, J. Hint1 expression inhibits proliferation and promotes radiosensitivity of human sgc7901 gastric cancer cells. Oncology Letters 16(2):2135-2142, 2018. e-Pub 2018. PMID: 30008911.
47. Xu, Z, Cao, C, Xia, H, Shi, S, Hong, L, Wei, X, Gu, D, Bian, Jm, Liu, Z, Huang, W, Zhang, Y, He, S, Lee, NP, Chen, J. Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma. Frontiers of Medicine 10(1):52-60, 2016. e-Pub 2016. PMID: 26809466.
48. Xia, B, Hong, L, Cai, XW, Zhu, Z, Liu, Q, Zhao, K, Fan, M, Mao, JF, Yang, HJ, Wu, KL, Fu, XL. Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer. International Journal of Radiation Oncology Biology Physics 91(3):517-523, 2015. e-Pub 2015. PMID: 25481679.
49. Xu, Z, Huo, X, Tang, C, Ye, H, Nandakumar, V, Lou, F, Zhang, D, Jiang, S, Sun, H, Dong, H, Zhang, G, Liu, Z, Dong, Z, Guo, B, Yan, H, Yan, C, Wang, L, Su, Z, Li, Y, Gu, D, Zhang, X, Wu, X, Wei, X, Hong, L, Zhang, Y, Yang, J, Gong, Y, Tang, C, Jones, L, Huang, XF, Chen, SY, Chen, J. Frequent KIT mutations in human gastrointestinal stromal tumors. Scientific reports 4, 2014. e-Pub 2014. PMID: 25080996.
50. Xu, Z, Huo, X, Ye, H, Tang, C, Nandakumar, V, Lou, F, Zhang, D, Dong, H, Sun, H, Jiang, S, Zhang, G, Liu, Z, Dong, Z, Guo, B, He, Y, Yan, C, Wang, L, Su, Z, Li, Y, Gu, D, Zhang, X, Wu, X, Wei, X, Hong, L, Zhang, Y, Yang, J, Gong, Y, Tang, C, Jones, L, Huang, XF, Chen, SY, Chen, J. Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform. PloS one 9(7), 2014. e-Pub 2014. PMID: 25025766.
51. Hong, L, Wei, X, Chen, J, Shi, Y. Overexpression of periostin predicts poor prognosis in non-small cell lung cancer. Oncology Letters 6(6):1595-1603, 2013. e-Pub 2013. PMID: 24273600.
52. Hong, L, Sun, HM, Lv, X, Yang, D, Zhang, J, Shi, Y. Expression of periostin in the serum of NSCLC and its function on proliferation and migration of human lung adenocarcinoma cell line (A549) in vitro. Molecular Biology Reports 37(5):2285-2293, 2010. e-Pub 2010. PMID: 19688273.
53. Sun, HM, Hong, L, Shen, XK, Lin, XQ, Song, Y, Shi, Y. Antithrombin-III without concomitant heparin improves endotoxin-induced acute lung injury rats by inhibiting the activation of mitogen-activated protein kinase. Chinese medical journal 122(20):2466-2471, 2009. e-Pub 2009. PMID: 20079161.
54. Sun, HM, Shi, Y, Song, Y, Lin, XQ, Shen, XK, Hong, L. Effect of heparin upon inflammatory reaction of endotoxin-induced acute lung injury in rat. National Medical Journal of China 89(38):2722-2725, 2009. e-Pub 2009. PMID: 20137277.
55. Shen, XK, Hong, L, Sun, HM, Shi, M, Song, Y. The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncology reports 22(3):535-539, 2009. e-Pub 2009. PMID: 19639200.
56. Wang, Y, Yu, Z, Wang, T, Zhang, J, Hong, L, Chen, L. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer 56(2):289-294, 2007. e-Pub 2007. PMID: 17267069.

Review Articles

1. Qin, K, Hong, L, Zhang, J, Le, X. MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer. Cancers 15(3), 2023. e-Pub 2023. PMID: 36765572.
2. Coleman, N, Hong, L, Zhang, J, Heymach, JV, Hong, DS, Le, X. Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. ESMO Open 6(6), 2021. e-Pub 2021. PMID: 34837746.
3. Tran, HT, Lam, VK, Elamin, YY, Hong, L, Colen, R, Elshafeey, N, Hassan, IA, Altan, M, Blumenschein, GR, Rinsurongkawong, W, Rivera, MJ, Vasquez, ME, Carter, B, Byers, LA, Tsao, A, Gibbons, DL, Fossella, FV, Glisson, BS, Zhang, J, Heymach, JV. Clinical outcomes in non-small-cell lung cancer patients treated with EGFR-tyrosine kinase inhibitors and other targeted therapies based on tumor versus plasma genomic profiling. JCO Precision Oncology 5:1241-1249, 2021. e-Pub 2021. PMID: 34377884.
4. Hong, L, Zhang, J, Heymach, JV, Le, X. Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer. Therapeutic Advances in Medical Oncology 13, 2021. e-Pub 2021. PMID: 33643443.

Abstracts

1. King NP, Fayngor R, Hong L, Nguyen RH, Sui D, Rinsurongkawong W, Young E, Lee J, Altan M, Zhang B, Vokes NI, Le X, Tran HT, Araujo HA, Gibbons DL, Vaporciyan AA, Heymach JV, Zhang J, Lin JK. Race-associated clinicogenomic predictors in non-small cell lung cancer treated with immune checkpoint inhibitors. ASCO, 2026. e-Pub 2026.
2. Hong L, Tian Y, Corredor M, Swift SZ, Li H, Alvarez FR, Rinsurongkawong W, Young E, Gibbons DL, Vaporciyan AA, Lee J, Roy-Chowdhuri S, Routbort M, Le X, Elamin YY, Vokes NI, Heymach JV, Solis LM, Navin N, Zhang J. Clinicogenomic profile and progression patterns in lung squamous cell carcinoma treated with immune checkpoint inhibitors. ASCO, 2026. e-Pub 2026.
3. Boiarsky D, Hong L, Ricciuti B, Cooper AJ, Saad MB, Elkrief A, Federico AD, Aminu M, Rinsurongkawong W, Le X, Luo J, Wu J, Gibbons DL, Heymach JV, Skoulidis F, Kim SY, Schoenfeld AJ, Awad MM, Zhang J, Vokes NI. Machine learning to identify biomarkers of response to immunotherapy in KRAS wildtype (KRASwt) non-small cell lung cancer (NSCLC). ASCO, 2026. e-Pub 2026.
4. Santo V, Mankuzhy N, Beshiri K, Celarier A, Hong L, Mingo EC, Pannu S, Pecci F, Garbo E, Gariazzo E, Brunetti L, Aijaz A, Monaca F, Chaft JE, Corassa M, Cortellini A, Vokes NI, Aldea M, Shaverdian N, Ricciuti B. Post-progression treatment strategies and immunotherapy rechallenge sensitivity following chemoradiation and consolidation durvalumab in unresectable stage III NSCLC: The POST-PACIFIC study. ASCO, 2026. e-Pub 2026.
5. Pan K, Zheng M, Xia Y, Zhang Y, Sun F, Borgeaud M, Singhal S, Hong L, Zhang J, Li W, Riess JW, Heymach JV, Myall NJ, Addeo A, Tan DS, Wu Y, Le X. Leptomeningeal disease in ALK-positive NSCLC: Survival impact of third-generation ALK inhibitors. ASCO, 2026. e-Pub 2026.
6. Ricciuti B, Awad MM, Jeng MY, Thummalapalli R, Hong L, Gariazzo E, Gorria T, Mountzios GS, Monaca F, Pecci F, Cortellini A, Corassa M, Mezquita L, Metro G, Derosa L, Schoenfeld AJ, Vokes NI. Indefinite versus 2 years fixed duration of immune checkpoint inhibition in metastatic non–small cell lung cancer. ASCO, 2026. e-Pub 2026.
7. Liew S, Jeng MY, Hong L, Pecci F, Gariazzo E, Santo V, Brunetti L, Hidalgo-Filho CM, Barbie DA, Vokes NI, Schoenfeld AJ, Ricciuti B. Prognostic significance of STK11, KEAP1, and NFE2L2-mutations in lung squamous cell carcinoma treated with immunotherapy with or without chemotherapy. ASCO, 2026. e-Pub 2026.
8. Boiarsky D, Hong L, Ricciuti B, Cooper AJ, Saad MB, Elkrief A, Federico AD, Aminu M, Rinsurongkawong W, Le X, Luo J, Wu J, Gibbons DL, Heymach JV, Skoulidis F, Kim SY, Schoenfeld AJ, Awad MM, Zhang J, Vokes NI. Disentangling KEAP1 and STK11 in KRAS-mutant (KRASm) non–small cell lung cancer (NSCLC) treated with immunotherapy. ASCO, 2026. e-Pub 2026.
9. Xu H, Elamin YY, Hong L, Concannon K, Saad MB, Xu X, Amgad M, Li H, Qin K, Han X, Ismail S, Kitsel Y, Gandhi S, Antonoff MB, Wu CC, Carter BW, Shroff GS, Heeke S, Le X, Cascone T, Vokes N, Altan M, Gibbons DL, Jaffray D, Chang JY, Liao Z, Rice D, Vaporciyan A, G Swisher SG, Lee J, Zhang J, Heymach JV, Wu J. OncoTwin: A multimodal digital twin framework for predicting treatment response and guiding trial design in ALK-rearranged non-small-cell lung cancer. AACR, 2026. e-Pub 2026.
10. Boiarsky D, Hong L, Cooper A, Ricciuti B, Spurr L, Saad M, Elkrief A, Federico AD, Aminu M, Rinsurongkawong W, Lewis J, Gibbons D, Vaporciyan A, Le X, Lee JJ, Heymach J, Wu J, Pitroda SP, Awad M, Schoenfeld A, Zhang J, Vokes N. P1. 11.55 Identifying Patients Cured From Metastatic Non-Small Cell Lung Cancer (mNSCLC) With Anti-PD-(L) 1 Therapy. WCLC 20(10):S192, 2025. e-Pub 2025.
11. Aminu M, Zhu B, Saad M, Li H, Hong L, Qayati M, Mehmet A, Gandhi S, Soto LM, Rojas FR, Ou S, Santiago TI, Burns BA, Roger PC, Chen H, Jie Y, Stephen SG, Mara AB, Pozadzides JV, Blumenschein GJ, Gibbons DL, Cascone T, Elamin YY, Li X, Negrao MV, Skoulidis F, Anne T, Tu J, Lee JL, Wu J, Zhang J, Heymach JV, Vokes N. P1. 11.70 Immune Cell Infiltration and Spatial Associations in the Tumor Microenvironment Following Dual ICI or ICI-Chemotherapy. WCLC 20(10):S200, 2025. e-Pub 2025.
12. Li H, Godoy MCB, Qin K, Salehjahromi M, Negrao MV, Plummer CM, Zhang Z, Hong L, Heeke S, Le X, Vokes N, Zhang B, Araujo HA, Altan M, Wu CC, Antonoff MB, Ostrin EJ, Gibbons DL, Heymach JV, Lee JJ, Gerber DE, Wu J, Zhang J. EP.04.31 Nomogram for Predicting Lung Cancer-Free Survival in Patients With Persistent Pulmonary Nodules. WCLC 20(10):S668-S669, 2025. e-Pub 2025.
13. Perera ND, Hong L, Rinsurongkawong W, Young E, Sui D, McNeill LH, Rinsurongkawong V, Lewis J, Lee J, Altan M, Zhang B, Vokes NI, Le X, Tran HT, Araujo HA, Gibbons DL, Vaporciyan AA, Heymach J, Zhang J, Lin JK. Race-associated clinicogenomic correlates of outcomes to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer (NSCLC). ASCO, 2025. e-Pub 2025.
14. Boiarsky D, Hong L, Cooper AJ, Ricciuti B, Saad MB, Elkrief A, Federico AD, Aminu M, Rinsurongkawong W, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Lee J, Heymach J, Wu J, Awad MM, Schoenfeld AJ, Zhang J, Vokes NI. Molecular profiling of metastatic lung squamous cell carcinoma (mLUSC) to identify patients with differential response to immune checkpoint inhibitor (ICI) therapy. ASCO, 2025. e-Pub 2025.
15. Concannon K, Morris B, Diao L, Sahu M, Lewis W, Sun X, Heeke S, Zhang B, Tran H, Hong L, Rinsurongkawong W, Nguyen M, Qin K, Li H, Zhang J, Lee J, Wang J, Cardnell R, Gay C, Heymach J, Byers L. Smoking burden is associated with immunotherapy resistance in extensive stage small cell lung cancer. AACR, 2025. e-Pub 2025.
16. Saad MB, Al-Tashi Q, Hong L, Li W, Boiarsky D, Li S, Petranovic M, Wu CC, Carter B, Cascone T, Le X, Chang J, Gibbons DL, Vaporciyan AA, Lee J, Mirjalili S, Jaffray DA, Gainor JF, Lou Y, Ricciuti B, DiFederico A, Pecci F, Awad MM, Heymach JV, Vokes NI, Zhang J, Wu J. 1236 Machine learning-based clinico-genomic prediction of benefits to add chemotherapy to immunotherapy in metastatic non-small cell lung cancer. SITC, 2024. e-Pub 2024.
17. Muneer A, Showkatian E, Saad MB, Hong L, Aminu M, Salehjahromi M, Sujit SJ, Waqas M, Li W, Vokes NI, Wu CC, Carter B, Chang J, Cascone T, Le X, Wistuba II, Chung C, Jaffray DA, Gibbons DL, Vaporciyan AA, Lee J, Heymach JV, Zhang J, Wu J. 1227 Predicting PD-L1 expression from CT scans using deep learning to guide immunotherapy in metastatic non-small-cell lung cancer. SITC, 2024. e-Pub 2024.
18. Bandyopadhyay R, Rojas FR, Hong L, Saad MB, Showkatian E, Vokes NI, Kalhor N, Haymaker CL, Wu CC, Carter B, Chang J, Le X, Cascone T, Jaffray DA, Gibbons DL, Vaporciyan AA, Lee J, Wistuba II, Heymach JV, Solis Soto LM, Zhang J, Wu J. 1198 Deep learning-driven pathomics signatures enhance patient stratification and prognosis in mNSCLC treated with immune checkpoint inhibitors. SITC, 2024. e-Pub 2024.
19. Aminu M, Zhu B, Vokes NI, Chen H, Hong L, Jian-Rong L, Junya F, Poteete A, Nilsson M, Le X, Cascone T, Jaffray DA, Nicholas N, Averett BL, Gibbons DL, Heymach JV, Chen K, Cheng C, Zhang J, Wu J. 1196 Unveiling immune evolution in lung pre-cancer through graph contrastive learning of spatial transcriptomics. SITC, 2024. e-Pub 2024.
20. Trevino S, Chen H, Halliday A, Ren X, Du R, Hong L, Poteete A, Zhu B, Nilsson M, Aminu M, Rinsurongkawong W, Rinsurongkawong V, Lee J, Blumenschein G, Gay C, Negrao MV, Altan M, Cascone T, Elamin Y, Skoulidis F, Tran H, Antonoff M, Vaporciyan AA, Wu J, Kurie J, Gibbons DL, Zhang J, Heymach JV, Le X, Vokes NI. 578 Defining immune and tumor resistant cell states to targeted vs immune therapy in non-small cell lung cancer (NSCLC). SITC, 2024. e-Pub 2024.
21. Salehjahromi M, Hong L, Li H, Kitsel Y, Godoy M, Wu CC, Antonoff M, Toumazis I, Ostrin E, Heeke S, Vokes NI, Le X, Vaporciyan AA, Lee J, Heymach JV, Zhang J, Wu J. 1238 Predicting lung cancer risk with CT radiomics: implications for immunoprevention. SITC, 2024. e-Pub 2024.
22. Saini A, Elkrief A, Hong L, Ricciuti B, Garbo E, Pecci F, Makarem M, Federico A, Gandhi MM, Aldea M, Nishino M, Sholl LM, Vokes NI, Schoenfeld AJ, Awad MM. P2. 11B. 02 Genomic Correlates of Response to Chemoimmunotherapy in STK11MUT and KEAP1MUT Metastatic Non-Small Cell Lung Cancer. WCLC, 2024. e-Pub 2024.
23. Zhang JJ, Tran H, Hong L, Li H, Qin K, Rinsurongkawong W, Vokes N, Le X, Skoulidis F, Cascone T, Hubert S, Wu J, Lee JJ, Byers L, Gibbons D, Vaporciyan A, Heymach J. Harnessing Real-World Data for Translational Research in Lung Cancer: MD Anderson GEMINI Program. WCLC, 2024. e-Pub 2024.
24. Hong L, Aminu M, Young C, Rinsurongkawong W, Li H, Qin K, Elamin Y, Sepesi B, Gibbons DL, Vaporciyan AA, Lee J, Roy-Chowdhuri S, Routbort MJ, Le X, Heymach JV, Wu J, Zhang J, Vokes N. Clinicogenomic Profile of Different Resistance Patterns to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. WCLC, 2024. e-Pub 2024.
25. Ricciuti B, Hong L, Gariazzo E, Gorria T, Thummalapalli R, Awosika N, Ludovica M, Fabrizio C, Gandhi M, Elkrief A, Pecci F, Alessi J, Federico AD, Makarem M, Saini A, Aldea M, Garbo E, Espinar JB, Ferrara R, Alessio C, Pinato D, Schoenfeld AJ, Nana FA, Mezquita L, Metro G, Vokes N, Awad MM. Clinical outcomes and immunotherapy retreatment in patients with metastatic NSCLC who complete at least two years of immune checkpoint blockade. WCLC, 2024. e-Pub 2024.
26. Li H, Hong L, Jin Y, Rocha P, Wistuba IL, Solis Soto LM, Arrechedera CA, Young C, Vokes N, Wu J, Rinsurongkawong W, Lee J, Gibbons DL, Vaporciyan AA, Heymach JV, Le X, Fan Y, Zhang J. A Multicenter Retrospective Study Reveals High MET Expression Associated with Superior Benefit from Immunotherapy in Advanced Non-Small Cell Lung Cancer Patients. WCLC, 2024. e-Pub 2024.
27. Boiarsky D, Hong L, Ricciuti B, Cooper A, Saad MB, Elkreif A, Federico AD, Aminu M, Rinsurongkawong W, Lewis J, Vaporciyan A, Le X, Lee J, Luo J, Wu J, Negrao MV, Gibbons DL, Heymach JV, Skoulidis F, Schoenfeld A, Awad MM, Zhang J, Vokes NI. Machine learning-based clinicogenomic prediction of response to PD-(L)1 inhibition in KRAS altered non-small cell lung cancer. WCLC, 2024. e-Pub 2024.
28. Cooper AJ, Ricciuti B, Gagne A, Federico AD, Awad MM, Aldea M, Ghigna MR, Grecea M, Chaft JE, Kris MG, Riely GJ, Rudin CM, Dagogo-Jack I, Hung YP, Mino-Kenudson M, Hong L, Kalhor N, Vokes N, Rekhtman N, Schoenfeld AJ. Clinical characteristics and outcomes of patients with SMARCA4-deficient undifferentiated thoracic tumors. WCLC, 2024. e-Pub 2024.
29. Pan K, Hong L, Zhang J, Byers L, Gibbons D, Heymach J, Beckham T, Ferguson S, Le X. Clinical characteristics and outcomes in patients with leptomeningeal disease (LMD) from non-small cell lung cancer. WCLC, 2024. e-Pub 2024.
30. Federico AD, Hong L, Elkrief A, Thummalapalli R, Cooper AJ, Shaverdian N, Ricciuti B, Machado Alessi JV, Giglio AD, Pecci F, Lamberti G, Gandhi MM, Sholl LM, Nishino M, Ardizzoni A, Heist RS, Arbour KC, Schoenfeld AJ, Vokes NI, Awad MM. TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma. ASCO, 2024. e-Pub 2024.
31. Boiarsky D, Hong L, Ricciuti B, Cooper AJ, Saad MB, Elkrief A, Federico AD, Aminu M, Rinsurongkawong W, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Lee J, Heymach J, Wu J, Schoenfeld AJ, Awad MM, Zhang J, Vokes NI. Efficacy and clinicogenomic biomarkers of response to dual versus single agent checkpoint inhibitor therapy in untreated metastatic non-small cell lung cancer. ASCO, 2024. e-Pub 2024.
32. Hong L, Federico AD, Aminu M, Ricciuti B, Machado Alessi JV, Rinsurongkawong W, Elamin YY, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Lee J, Le X, Heymach J, Wu J, Awad MM, Zhang J, Vokes NI. PD-L1 expression in pulmonary sarcomatoid carcinoma and response to immunotherapy. ASCO, 2024. e-Pub 2024.
33. Zhu B, Chen P, Aminu M, Fujimoto J, Hong L, Moreira AL, Li J, Tian Y, Solis Soto LM, Edwin Roger PC, Shi O, Chen H, Rojas FR, Vilar E, Maitra A, Chen K, Navin N, Haymacker CL, Velcheti V, Sterman DH, Futreal P, Gibbons DL, Wistuba II, Heymach JV, Cheng C, Pass HI, Wu J, Zhang J. Spatial single-cell immune microenvironment analysis reveals the transition from innate to adaptive immune response during early lung adenocarcinoma carcinogenesis. AACR, 2024. e-Pub 2024.
34. Federico AD, Hong L, Elkrief A, Thummalapalli R, Ricciuti B, Alessi J, Gogia P, Pecci F, Gandhi M, Ladanyi M, Zhang J, Gibbons D, Heymach J, Nishino M, Sholl L, Awad M, Arbour KC, Schoenfeld A, Vokes N, Luo J. 229P Clinicopathologic and genomic features of patients with mucinous lung adenocarcinoma and response to systemic therapies. ESMO Open, 2024. e-Pub 2024.
35. Qin K, Wang K, Li S, Hong L, Waree R, Hubert S, Le X, Vokes N, Altan M, Gibbons DL, Heymach J, Lee JJ, Lou Y, Zhang J. EP11. 03-39 Platinum/Taxane versus Docetaxel+/-Ramucirumab for Metastatic Lung Cancers That Progressed on Platinum Doublets and Anti-PD1/PD-L1. WCLC, 2023. e-Pub 2023.
36. Le X, Robichaux JP, Nilsson MB, Ramaswamy V, Ravichandran A, Wu J, Elamin YY, Hong L, Udagawa H, Socinski M, Bhat G, Lebel F, Vincent S, Bunn V, Su Z, Lawson J, Cross J, Heymach J. 1377P Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity. ESMO, 2023. e-Pub 2023.
37. Thummalapalli R, Ricciuti B, Bandlamudi C, Muldoon D, Luo J, Machado Alessi JV, Pecci F, Lamberti G, Hong L, Plodkowski AJ, Ladanyi M, Chaft JE, Rudin CM, Kris MG, Riely GJ, Vokes NI, Awad MM, Schoenfeld AJ. Clinical and molecular features of long-term response to anti-PD-(L) 1 therapy in patients with advanced non-small cell lung cancer. ASCO, 2023. e-Pub 2023.
38. Li H, Qin K, Zhang Z, Hong L, Wu CC, Barco Godoy MC, Antonoff M, Ostrin EJ, Toumazis I, Gibbons DL, Heymach J, Lee J, Wu J, Zhang J. Cancer risk assessment in patients with persistent pulmonary nodules and its correlation with cancer-free survival. ASCO, 2023. e-Pub 2023.
39. Qin K, Wang K, Li S, Hong L, Rinsurongkawong W, Hubert SM, Le X, Vokes NI, Altan M, Gibbons DL, Heymach J, Lee J, Lou Y, Zhang J. Association of docetaxel efficacy with cancer gene mutation status in patients with metastatic non-small-cell lung cancer who progressed on platinum doublets and immunotherapy. ASCO, 2023. e-Pub 2023.
40. Zhu B, Li J, Chen H, Chen P, Fujimoto J, Tian Y, Aminu M, Li C, Hong L, Reuben A, Parra Cuentas ER, Shi O, Nilsson M, Poteete A, Hubert S, Khan K, Lu W, Kraushaar D, Song X, Zhang J, Gibbons D, Soto LS, Wistuba I, Wu J, Heymach J, Cheng C, Zhang J. Single cell and spatial profiling reveal molecular and immune evolution from precancers to invasive lung adenocarcinomas in genetic and carcinogen-induced mouse models. AACR, 2023. e-Pub 2023.
41. Aminu M, Vokes NI, Saad MB, Li H, Hong L, Mohamed MS, Boom J, Chen P, Altan M, Gandhi S, Swisher S, Antonoff MB, Pozadzides JV, Jr GB, Gibbons DL, Cascone T, Elamin YY, Le X, Negrao MV, Skoulidis F, Tsao AS, Tu J, Lee J, Zhang J, Heymach JV, Wu J. Tumor volumetric analysis to correlate disease burden with response to dual immune checkpoint blockade in metastatic NSCLC. AACR, 2023. e-Pub 2023.
42. Chen P, Rojas F, Hu X, Fujimoto J, Serrano A, Zhu B, Hong L, Bandyopadhyay R, Aminu M, Saad MB, Salehjahromi M, Sujit SJ, Kalhor N, Pass HI, Moreira AL, Wistuba II, Gibbons DL, Heymach JV, Solis Soto LM, Zhang J, Wu J. Pathomics reveals the molecular and immune evolution from lung preneoplasia to invasive adenocarcinoma. AACR, 2023. e-Pub 2023.
43. Hong L, Aminu M, Lu X, Saad MB, Chen P, Rinsurongkawong W, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Lee J, Roy-Chowdhuri S, Routbort MJ, Heymach JV, Wu J, Zhang J, Vokes NI. Genomic and clinical predictors of early disease progression and chemoimmunotherapy benefit in advanced NSCLC. AACR, 2023. e-Pub 2023.
44. Hong L, Drusbosky L, Wang Y, Xiong Y, Chen R, Heeke S, Nilsson MB, Zhang J, Heymach JV, Le X. Mutation and co-mutation landscape of ERBB2 alterations in advanced NSCLC. AACR, 2023. e-Pub 2023.
45. Hong L, Du R, Lee J, Heymach JV, Le X. PP01. 43 A Retrospective Single-Center Analysis of Patients with Atypical EGFRm NSCLC Treated with First-Line EGFR-TKIs. NACLC, 2023. e-Pub 2023.
46. Le X, Du R, Lewis WE, Hong L, Skoulidis F, Byers L, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Baik C, Zhang J, Heymach J. EP08. 02-163 Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer. WCLC, 2022. e-Pub 2022.
47. Le X, Wang R, Vokes N, Elamin Y, Kalhor N, McGrail D, Xi Y, Santiago Treviño III, Hong L, Du R, Blumenschein G, Gay C, Negrao M, Altan M, Tran H, Hu L, Wang J, Heeke S, Nilsson M, Robichaux J, Dang M, Han G, Byers L, Tsao A, Sepesi B, Bernatchez C, Zhang J, Wang L, Heymach J. Enhanced lineage plasticity in RTK-independent TKI-resistant EGFR-mutant NSCLC. AACR, 2022. e-Pub 2022.
48. Hong L, Rinsurongkawong W, Saad MB, Chen P, Aminu M, Spelman AR, Negrao MV, Cascone T, Lin SH, Lee P, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Lee J, Le X, Wu J, Heymach J, Zhang J, Vokes NI. Real-world effectiveness of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic non–small cell lung cancer. ASCO, 2022. e-Pub 2022.
49. Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Wu CC, Rinsurongkawong W, Spelman AR, Negrao MV, Cascone T, Lin SH, Lee P, Sepesi B, Gibbons DL, Vaporciyan AA, Lee J, Le X, Zhang J, Wu J, Heymach J. Deep learning signature from chest CT and association with immunotherapy outcomes in EGFR/ALK-negative NSCLC. ASCO, 2022. e-Pub 2022.
50. Drusbosky LM, Hong L, Xiong Y, Chen R. Clinical profile and co-alterations of ERBB2 in NSCLC. AACR-JCA Joint Conference, 2022. e-Pub 2022.
51. Hong L, Rinsurongkawong W, Rinsurongkawong V, Spelman AR, Lewis J, Gandhi SJ, Antonoff MB, Gibbons DL, Vaporciyan AA, Lee JJ, Heymach JV, Zhang J, Vokes NI. 1328P Outcomes from local consolidative therapy and immune checkpoint inhibitors in metastatic non-small cell lung cancer. ESMO, 2021. e-Pub 2021.
52. Le X, Hong L, Kemp H, Saam J, Hensel C, Raymond V, Zhang J, Heymach J. FP07. 10 Circulating Tumor DNA Analysis in NSCLC with MET exon 14 Skipping Alterations. WCLC, 2021. e-Pub 2021.
53. Tran H, Lam VK, Vasquez M, Elamin Y, Raymond V, Hong L, Blumenschein G, Carter B, Lanman R, Altan M, Tsao A, Byers L, Gibbons D, Zhang J, Heymach JV. Comparable clinical benefits between low and high variant allelic frequency in NSCLC patients treated with targeted therapies based on molecular alterations from ctDNA NGS. AACR, 2020. e-Pub 2020.
54. Tran H, Lam V, Vasquez M, Hong L, Colen R, Elshafeey N, Hassan I, Papadimitrakopoulou V, Blumenschein G, Carter B, Simon G, Lanman R, Raymond V, Elamin Y, Altan M, Tsao A, Gibbons D, Zhang J, Heymach J. P1. 01-98 Outcomes in Advanced NSCLC Patients Treated with 1st Line EGFR-TKI Based on Mutation Detection from Tissue or cfDNA-Based Genomic Sequencing. IASLC World Conference Lung Cancer WCLC, 2019. e-Pub 2019.
55. Hong L, Dibaj S, Negrao MV, Reuben A, Roarty E, Rinsurongkawong W, Lewis J, Gibbons DL, Sepesi B, Papadimitrakopoulou V, Glisson BS, Blumenschein Jr GR, Futreal PA, Wistuba II, Roth JA, Swisher S, Heymach J, Simon GR, Lee J, Zhang J. Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC). American Society of Clinical Oncology, 2019. e-Pub 2019.
56. Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, Chen R, Abbas H, Zhong J, Chen H, Dong Z, Zhu X, Li J, Roarty E, Rinsurongkawong W, Lewis J, Futreal A, Xia X, Zhang J, Zhao J. cfDNA analysis to reveal association of genomic features with chemotherapy response and survival in patients with pulmonary large-cell neuroendocrine carcinoma. ASCO, 2019. e-Pub 2019.
57. Tran H, Lam V, Vasquez M, Hong L, Colen R, Elshafeey N, Hassan I, Prado E, Papadimitrakopoulou V, Blumenschein G, Carter B, Simon G, Byers L, Altan M, Elamin Y, Lanman R, Raymond V, Tsao A, Gibbons D, Fossella F, Zhang J, Heymach J. P1. 13-37 clinical evaluation of plasma-based (cfDNA) genomic profiling in over 1,000 patients with advanced non-small cell lung cancer. WCLC, 2018. e-Pub 2018.
58. Chen J, Xu Z, Zhao T, Gu D, Hong L, Zhang E. Effect of H3K27 acetylation activated-long noncoding RNA CCAT1 on cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous carcinoma cell. ASCO, 2016. e-Pub 2016.